Medincell SA logo

Medincell SA

NEW
XPAR:MEDCL (France)  
€ 15.30 (+1.73%) Oct 30
At Loss
Market Cap:
€ 445.01M ($ 484.06M)
Enterprise V:
€ 484.51M ($ 527.03M)
Volume:
42.18K
Avg Vol (2M):
59.24K
Trade In:
Volume:
42.18K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Medincell ( XPAR:MEDCL ) from 2018 to Oct 31 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Medincell stock (XPAR:MEDCL) PE ratio as of Oct 31 2024 is 0. More Details

Medincell SA (XPAR:MEDCL) PE Ratio (TTM) Chart

To

Medincell SA (XPAR:MEDCL) PE Ratio (TTM) Historical Data

Total 1180
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Medincell PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-10-31 At Loss 2024-08-29 At Loss
2024-10-30 At Loss 2024-08-28 At Loss
2024-10-29 At Loss 2024-08-27 At Loss
2024-10-28 At Loss 2024-08-26 At Loss
2024-10-25 At Loss 2024-08-23 At Loss
2024-10-24 At Loss 2024-08-22 At Loss
2024-10-23 At Loss 2024-08-21 At Loss
2024-10-22 At Loss 2024-08-20 At Loss
2024-10-21 At Loss 2024-08-19 At Loss
2024-10-18 At Loss 2024-08-16 At Loss
2024-10-17 At Loss 2024-08-15 At Loss
2024-10-16 At Loss 2024-08-14 At Loss
2024-10-15 At Loss 2024-08-13 At Loss
2024-10-14 At Loss 2024-08-12 At Loss
2024-10-11 At Loss 2024-08-09 At Loss
2024-10-10 At Loss 2024-08-08 At Loss
2024-10-09 At Loss 2024-08-07 At Loss
2024-10-08 At Loss 2024-08-06 At Loss
2024-10-07 At Loss 2024-08-05 At Loss
2024-10-04 At Loss 2024-08-02 At Loss
2024-10-03 At Loss 2024-08-01 At Loss
2024-10-02 At Loss 2024-07-31 At Loss
2024-10-01 At Loss 2024-07-30 At Loss
2024-09-30 At Loss 2024-07-29 At Loss
2024-09-27 At Loss 2024-07-26 At Loss
2024-09-26 At Loss 2024-07-25 At Loss
2024-09-25 At Loss 2024-07-24 At Loss
2024-09-24 At Loss 2024-07-23 At Loss
2024-09-23 At Loss 2024-07-22 At Loss
2024-09-20 At Loss 2024-07-19 At Loss
2024-09-19 At Loss 2024-07-18 At Loss
2024-09-18 At Loss 2024-07-17 At Loss
2024-09-17 At Loss 2024-07-16 At Loss
2024-09-16 At Loss 2024-07-15 At Loss
2024-09-13 At Loss 2024-07-12 At Loss
2024-09-12 At Loss 2024-07-11 At Loss
2024-09-11 At Loss 2024-07-10 At Loss
2024-09-10 At Loss 2024-07-09 At Loss
2024-09-09 At Loss 2024-07-08 At Loss
2024-09-06 At Loss 2024-07-05 At Loss
2024-09-05 At Loss 2024-07-04 At Loss
2024-09-04 At Loss 2024-07-03 At Loss
2024-09-03 At Loss 2024-07-02 At Loss
2024-09-02 At Loss 2024-07-01 At Loss
2024-08-30 At Loss 2024-06-28 At Loss

Medincell SA (XPAR:MEDCL) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.